In June 2024, Jiuzhitang Co., Ltd. announced that Mr. Xu Xiangping has resigned from his position as Vice General Manager of the company due to personal reasons. According to the official statement, his resignation took effect immediately upon delivery to the Board of Directors and will not affect the company’s normal operations or management. Jiuzhitang expressed sincere gratitude for Mr. Xu’s contributions during his tenure.During his time at Jiuzhitang, Mr. Xu was primarily responsible for strategic planning, market expansion, and certain operational functions, playing a positive role in the company’s transformation, upgrading, and brand development. His departure comes at a critical juncture as Jiuzhitang accelerates its strategy for modernizing and internationalizing traditional Chinese medicine, drawing some attention from investors. However, the company emphasized that its management team remains stable, and current executives will seamlessly assume his responsibilities to ensure continuity in strategic execution.As a time-honored Chinese herbal medicine enterprise with over 370 years of history, Jiuzhitang has recently focused on innovative TCM R&D, expansion into the broader health industry, and digital transformation. This executive change is part of routine personnel adjustments, and with a sound governance structure in place, the company remains committed to advancing its core strategies and achieving high-quality growth.
2024年6月，九芝堂股份有限公司发布公告，宣布公司副总经理徐向平先生因个人原因辞去所任职务。根据公告，徐向平的辞职自送达董事会之日起生效，其辞职不会影响公司日常经营与管理工作的正常开展。九芝堂在公告中对徐向平在任职期间为公司发展所作出的贡献表示衷心感谢。徐向平在九芝堂任职期间，主要负责公司战略规划、市场拓展及部分业务运营工作，在推动企业转型升级和品牌建设方面发挥了积极作用。他的离职正值九芝堂加速推进中医药现代化与国际化战略的关键阶段，因此引发部分投资者关注。不过，公司强调管理层团队稳定，现有高管将有序承接相关职责，确保战略执行连续性。九芝堂作为拥有370余年历史的中华老字号中药企业，近年来持续聚焦创新中药研发、大健康产业布局及数字化转型。此次人事变动属于正常高管调整，公司治理结构健全，未来仍将围绕核心战略稳步推进高质量发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/19533.html